The Traderszone Network

Published in TZ Latest News 3 August, 2017 by The TZ Newswire Staff

Juno Therapeutics’ Cash Position and Potential Cash Cow JCAR017 Are Still What’s Important

It’s been a pretty good year for Juno Therapeutics (NASDAQ: JUNO) so far. The clinical-stage biotech’s share price is up more than 50% year-to-date. Its financial position in the first quarter looked great thanks to its collaboration with Celgene (NASDAQ: CELG).

read more